1h Free Analyst Time
The NTRK fusion gene positive advanced solid tumor market is forecasted to grow by USD 92.6 million during 2023-2028, accelerating at a CAGR of 4.5% during the forecast period. The report on the NTRK fusion gene positive advanced solid tumor market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing incidence of cancer, increasing focus on the early detection of cancer, and growing demand for molecular diagnostics.
The NTRK fusion gene positive advanced solid tumor market is segmented as below:
By Application
- Clinical
- Research
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the NTRK fusion gene positive advanced solid tumor market covers the following areas:
- NTRK fusion gene positive advanced solid tumor market sizing
- NTRK fusion gene positive advanced solid tumor market forecast
- NTRK fusion gene positive advanced solid tumor market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the NTRK fusion gene positive advanced solid tumor market: Bayer AG, Empire Genomics Inc., F. Hoffmann La Roche Ltd., LGC Clinical Diagnostics Inc., NeoGenomics Laboratories Inc., and OncoDNA.Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is high demand for biomarker-based tests."
According to the report, one of the major drivers for this market is the increasing incidence of cancer.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bayer AG
- Empire Genomics Inc.
- F. Hoffmann La Roche Ltd.
- LGC Clinical Diagnostics Inc.
- NeoGenomics Laboratories Inc.
- OncoDNA
